Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buzhong Yiqi pills (also known as Buzhong Yiqi Wan) is a classic Traditional Chinese Medicine (TCM) formula originally described by Li Dongyuan in the 13th century. It is traditionally used to treat "Spleen and Stomach Qi deficiency" and "sinking of Qi," manifesting as fatigue, organ prolapse, and chronic diarrhea. The formula typically consists of eight herbs: *Astragalus membranaceus*, *Glycyrrhiza uralensis*, *Codonopsis pilosula* (or *Panax ginseng*), *Atractylodes macrocephala*, *Angelica sinensis*, *Cimicifuga heracleifolia*, *Bupleurum chinense*, and *Citrus reticulata*. In modern clinical research, it is being investigated for its immunomodulatory properties in autoimmune diseases. Specifically, Tangdu Hospital of the Fourth Military Medical University is conducting a Phase 2 clinical trial (ChiCTR2300073207) to evaluate the efficacy and safety of Buzhong Yiqi pills in preventing relapse among adult patients with myasthenia gravis who have achieved a stable clinical status. The drug is thought to work by balancing T-cell populations and reducing the production of pathogenic autoantibodies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on buzhong yiqi pills.